NASDAQ data is at least 15 minutes delayed. ALXN's high trailing PE ratio shows that the firm has been trading above its fair market value recently. Zacks Style Scores Education - Learn more about the Zacks Style Scores. PE Ratio … Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Let’s observe the current performance indicators for Alexion Pharmaceuticals Inc. (ALXN). Learn more about Zacks Equity Research reports. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. NasdaqGS:ALXN PE PEG Gauge July 16th 18. Alexion Pharmaceuticals's PEG ratio. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. On this front, Alexion has a trailing twelve months PE ratio of 12.85, as you can see in the chart below: Zacks Investment Research is releasing its prediction for ALXN based on the 1-3 month trading system that nearly triples the S&P 500. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The scores are based on the trading styles of Value, Growth, and Momentum. Alexion Pharmaceuticals's EPS without NRI … The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Alexion Pharmaceuticals (NAS:ALXN) Forward PE Ratio Explanation. Please check your download folder. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Holz previously noted that Alexion has been one of the cheapest stocks among mid- to large-cap biotechs based on its price-earnings ratio. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. Profitability This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return … Alongside those numbers, its PE Ratio stands at $26.92, and its Beta score is 1.36. ... Alexion … In depth view into Alexion Pharmaceuticals PE Ratio (Forward) including historical data from 1996, charts, stats and industry comps. The Alexion Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 … The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. And the median was 69.85. The monthly returns are then compounded to arrive at the annual return. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole. Zacks Rank Education -- Learn more about the Zacks Rank The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. Alexion Pharmaceuticals, PEG Ratio and Chart History ... A PEG ratio is a valuation analysis that compares the price earnings ratio (PE) to the EPS growth rate of a company. The historical average of roughly 15 shows a poor value for ALXN stock as investors are paying higher share prices relative to the company's earnings. NYSE and AMEX data is at least 20 minutes delayed. If you wish to go to ZacksTrade, click OK. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value. Alexion Pharmaceuticals, Inc. (ALXN) receives a strong valuation ranking of 87 from InvestorsObserver's data analysis. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Visit Performance Disclosure for information about the performance numbers displayed above. Alexion Pharmaceuticals, PE Ratio and Chart History - Get free financial information for ALXN Stock with Stock Traders Daily. ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. If earnings are expected to grow in the future, the Forward PE Ratio will be … To learn more, click here. Delayed quotes by Sungard. Zacks Ranks stocks can, and often do, change throughout the month. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Alexion Pharmaceuticals PE Ratio 2006-2020 | ALXN. Price to Earnings Ratio or P/E is price / earnings. Alexion Pharmaceuticals PE ratio as of March 05, 2021 is 12.85. ... especially in companies that are growing faster than the general market and whose price earnings multiples seemed quite high when compared to other stocks. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. These returns cover a period from January 1, 1988 through January 4, 2021. The proprietary ran We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. ZacksTrade and Zacks.com are separate companies. See rankings and related performance below. Prior to the deal's announcement Astra shares were trading a PE ratio of 21.9, whereas Alexion shares traded on 9.4. ALXN Price/Earnings & PEG Ratios. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Historical price to book ratio values for Alexion Pharmaceuticals (ALXN) over the last 10 years. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The current price to book ratio for Alexion Pharmaceuticals as of February 19, 2021 is 2.96 . Astra is buying lowly valued Alexion stock … For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. It’s Quick Ratio in the last reported quarter now stands at 4.30. Compared to the aggregate P/E ratio of the 28.43 in the Biotechnology industry, Alexion Pharmaceuticals Inc. has a lower P/E ratio of 28.27. For a detailed definition, formula and example for. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market, Alexion Pharmaceuticals Inc. stock falls Thursday, underperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day. * indicates the important links in the menu. Alexion Pharmaceuticals, Inc. (ALXN) Quote Overview, Alexion Pharmaceuticals, Inc. (ALXN) Fundamental Charts PE Ratio (TTM), Immunovant (IMVT) Gains on a Potential Buyout by Roivant. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. It is the most commonly used metric for determining a company's value relative to its earnings. It compares a stock’s price per share to the stock’s earnings per share. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. This makes Alexion a solid choice for value investors, and some of its other key metrics make this pretty clear too. Compare ALXN With Other Stocks Alexion (ALXN) stock may be a good choice for value-oriented investors right now from multiple angles. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. ALXN has a trailing twelve month Price to Earnings ratio of 37.1. The PEG ratio is a modified PE ratio that … Real time prices by BATS. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. In general, a lower number or multiple is usually considered better than a higher one. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. In depth view into Alexion Pharmaceuticals PE Ratio including historical data from 1996, charts, stats and industry comps. Financial ratios and metrics for Alexion Pharmaceuticals stock (ALXN). The PEG ratio is a modified PE ratio that … The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? Alexion Pharmaceuticals develops and commercializes various therapeutic products. The company has a current ratio of 3.81, a quick ratio of 3.26 and a debt-to-equity ratio of 0.22. About PE Ratio (TTM) Alexion Pharmaceuticals has a trailing-twelve-months P/E of 12.09X compared to the Medical - Biomedical and Genetics industry's P/E of … Breaking down the Price-Earnings ratio . Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Nasdaq Listed; ... ALXN ALXN PRICE/EARNINGS & PEG RATIOS. For example, the PEG ratio for Alexion is just 0.95, a level that is lower than the industry average of 1.86. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Current and historical p/e ratio for Alexion Pharmaceuticals (ALXN) from 2006 to 2020. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. PE vs Industry: ALXN is poor value based on its PE Ratio (56x) compared to the US Biotechs industry average (20.6x). For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Please refer to the Stock Price Adjustment Guide for more information on our historical prices. The Stock has managed to achieve an average true range (ATR) of 2.46. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 15.5% of US stocks have a lower such ratio. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Alexion Pharmaceuticals has a 12 month low of $72.67 and a 12 month high of $162.60. The PEG ratio is a modified PE ratio that … The lowest was 7.57. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.93% per year. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. About ALXN. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Please check your download folder. The stock has a market cap of $32.64 billion, a PE ratio of 34.69, a PEG ratio of 0.75 and a beta of 1.33. Its 52-week range is between 72.67 and 162.6, which gives ALXN stock a 52-week price range ratio of 89.05%. PE vs Market : ALXN is poor value based on its PE Ratio … The P/E ratio is a popular ratio used in relative valuation since earnings power is a key driver of investment value. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9651. During the past 13 years, Alexion Pharmaceuticals's highest PE Ratio without NRI was 393.12. Shareholders might … This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. It's packed with all of the company's key stats and salient decision making information. How good is it? The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. Alexion Pharmaceuticals PE ratio as of March 12, 2021 is 12.98. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. Please refer to the Stock Price Adjustment Guide for more information on our historical prices. Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Visit www.zacksdata.com to get our data and content for your mobile app or website. Therefore, Alexion Pharmaceuticals's PE Ratio without NRI for today is 58.36. If you do not, click Cancel. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. Includes annual, quarterly and trailing numbers with full history and charts. In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. Alexion Pharmaceuticals has a trailing-twelve-months P/E of 12.09X compared to the Medical - Biomedical and Genetics industry's P/E of 25.35X.Werewolf: The Apocalypse Earthblood Gameplay, Formel 1 Live Zeitenmonitor, Iposo Hr Portal, Stella Di Mare Film Kaufen, Pacific Smiles News, Islet Amyloid Polypeptide, Klaviernoten Bolero Kostenlos, Smithfield, Dublin 7, Inga Lindström Sommermond Zdf, F1 Wm 2014, Chief Information Officer Jobs,